Understanding Chronic Lymphocytic Leuke… | Clinical Trial

Key information

Conditions

Chronic Lymphocytic Leukemia Chronic Disease Disease Attributes Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, B-Cell Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States

Location status: Recruiting

Location contact

Jennifer Brown, MD, PhD

CONTACT

[email protected]

617-582-8437

Jennifer Brown, MD, PhD

PRINCIPAL_INVESTIGATOR

About this study

The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia, for the potential development of more effective therapies for this disease.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

New and existing patients seen for treatment of monoclonal B-cell lymphocytosis
Any low grade lymphoproliferative disorder
Chronic Lymphocytic Leukemia in the Dana Farber Cancer Institute Hematologic Oncology Clinic or elsewhere

Exclusion criteria

-

Treatment and study plan

Primary outcomes

Incidence of novel genomic prognostic markers in Chronic Lymphocytic Leukemia

Time frame: 20 years

Exploratory science to better understand Chronic Lymphocytic Leukemia

Study contacts

Contact information is provided by the study sponsor or research team.

Jennifer Brown, MD, PhD

CONTACT

[email protected]

617-582-8437

Sponsors and collaborators

Lead sponsor

Dana-Farber Cancer Institute

Other

Collaborators

National Cancer Institute (NCI)

Registry information

Important dates

Study start: 1999
Primary completion: 2030
Study completion: 2032
First posted: Jul 22, 2019
Registry last updated: Apr 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting